Tumour-dissolving adenovirus mutant possessing multiple specific anti-tumour mechanism

Abstract

This invention involved oncolytic adenovirus mutant with the multiple antitumoral Mec. It belongs to the BME field. The adenovirus mutant Elb-55kDa and Elb-19kDa has missing gene, inserts chimeric promoter composed by the human telomerase reverse transcriptase core sequence and human tumor epidermal growth factor receptor enhancer before the replication required gene Ela codons mEla289R and mEla243R. So the virus can specific proliferate in cancer cell. Oncolytic viruses and mEla protein can exert thire influence. It can also increase the sensitivity of cancer cell to chemoradiation and have no influence to normal cell. It inserts the human h-endostatin gene expression cassette in adenovirus mutant gene group; along the replication of virus in cancer cell to amplificate h-endostatin gene and effective expression in tumor so to restrain neovascularization of tumor so to realize the result of restrain the increase and transformation of cancer cell and apoptotic cell. This new oncolytic adenovirus mutant has good clinical prospect in gene curing so to used in curing many kinds of human tumors.

Description

technical field [0001] The invention relates to an oncolytic adenovirus mutant with multiple specific anticancer mechanisms applied to tumor treatment, belonging to the fields of life science and biomedicine. Background technique [0002] Malignant tumors are a large class of diseases characterized by abnormal cell proliferation and metastasis. In 2000, there were about 10 million new cancer cases worldwide, 6.2 million deaths, and 22 million current cases. The morbidity and mortality of tumors in my country have been on the rise. In 2000, the number of cancer patients was about 1.8-2 million, and the number of deaths was 1.4-1.5 million. Among urban residents, tumors have accounted for the first cause of death. However, with the development of society and economy, the main risk factors of tumors have not been effectively controlled. At present, the treatment of malignant tumors is still dominated by conventional surgery, radiotherapy, and chemotherapy. This conventional t...

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to provide an oncolytic adenovirus mutant with multiple specific anti-cancer mechanisms that has good clinical application prospects and can be used for the treatment of various tumors. The oncolytic virus and anti-cancer gene recombinants overcome the current replication Defective adenoviral vectors (such as Ad-p53) have the disadvantages of low efficiency and no targeting of anti-cancer gene transfer and expression, and overcome the shortcomings of proliferative and replicative adenoviral vectors (such as H101, ONYX-015) which only have a single anti-tumor mechanism and are safe. Poor sex and other shortcomings, its anti-tumor efficacy can be improved, and the safety can be improved